microRNA-145-5p inhibits prostate cancer bone metastatic by modulating the epithelial-mesenchymal transition

Luo, Bingfeng; Yuan, Yuan; Zhu, Yanyan; Liang, Song-Wu; Dong, Ru‐Nan; Hou, Jing; Li, Ping; Xing, Yaping; Lü, Zhiyong; Lo, R.; Kuang, Guan‐Ming

doi:10.3389/fonc.2022.988794

Cited by 4 publications

(4 citation statements)

References 35 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-145-5p has garnered attention for its inhibitory effects on the proliferation and progression of various cancers, including colorectal cancer [37], breast cancer [38] and bladder cancer [39]. Additionally, it also plays a crucial role in prostate cancer by impeding bone metastasis [40] and restraining neuroendocrine differentiation [41]. However, there is a scarcity of research on therapeutic drugs targeting miR-145-5p in the eld of tumor studies, especially for CRPC.…”

Section: Discussionmentioning

confidence: 99%

Trillin-Mediated Inhibition of NF-κB/COX-2 Signaling Pathways through Upregulation of miR-145-5p Targeting MAP3K11 in Castration-Resistant Prostate Cancer

Wang,

Peng,

Hao

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose Prostate cancer remains a leading cause of cancer-related deaths among men worldwide, driving the need for innovative therapeutic avenues. Despite preliminary evidence supporting the anti-cancer potential of the natural compound Trillin, its effectiveness against castration-resistant prostate cancer (CRPC) has yet to be fully explored. Methods This study evaluated the anti-cancer efficacy of Trillin in CRPC cell lines DU145 and PC3 through a comprehensive set of in vitro and in vivo experiments. Assessments included cell proliferation, migration, invasion, apoptosis, and cell cycle analyses, alongside Western blot, qRT-PCR, confocal immunofluorescence, and dual luciferase assays to elucidate the molecular mechanisms underlying Trillin's action. Additionally, an in vivo CRPC xenograft model in NYG immunodeficient mice was used to assess therapeutic efficacy and toxicity. Results Trillin treatment significantly reduced CRPC cell viability, proliferation, migration, and invasion, while inducing apoptosis and cell cycle arrest at the G0/G1 phase. Mechanistically, Trillin downregulated key proteins involved in the NF-κB/COX-2 pathway, inhibited nuclear translocation of NF-κB subunits, and decreased COX-2 promoter activity. It also upregulated miR-145-5p, targeting MAP3K11, which is implicated in CRPC progression. In vivo, Trillin markedly suppressed tumor growth without observable toxicity, highlighting its potential as a therapeutic agent. Conclusion Our findings demonstrate that Trillin significantly inhibits the growth and metastatic capabilities of CRPC cells, both in vitro and in vivo, through induction of apoptosis, cell cycle arrest, and suppression of the NF-κB/COX-2 signaling pathway. By modulating miR-145-5p and targeting MAP3K11, Trillin presents a promising therapeutic strategy for CRPC, warranting further clinical investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Trillin-Mediated Inhibition of NF-κB/COX-2 Signaling Pathways through Upregulation of miR-145-5p Targeting MAP3K11 in Castration-Resistant Prostate Cancer

Wang,

Peng,

Hao

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Luo et al. ( 72 ) showed that miRNA-145-5p had the ability to suppress growth, motility, and invasiveness of bone metastatic PCa cells. Additionally, miRNA-145-5p could suppress the expression of bFGF, IGF, and TGF-β in PC3 cells.…”

Section: Association Of Mirna With Pca Bone Metastasismentioning

confidence: 99%

“…Both miR-582-3p and miR-582-5p suppressed the TGF-b pathway by targeting its multiple elements including SMAD2, SMAD4, TGF-b receptor I (TGFBRI), and TGFBRII. Luo et al (72) showed that miRNA-145-5p had the ability to suppress growth, motility, and invasiveness of bone metastatic PCa cells. Additionally, miRNA-145-5p could suppress the expression of bFGF, IGF, and TGF-b in PC3 cells.…”

Section: Tgf-b Signaling Pathwaymentioning

confidence: 99%

The regulatory process and practical significance of non-coding RNA in the dissemination of prostate cancer to the skeletal system

Sang,

Li,

Zhao

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Prostate cancer is a major contributor to male cancer-related mortality globally. It has a particular affinity for the skeletal system with metastasis to bones seriously impacting prognosis. The identification of prostate cancer biomarkers can significantly enhance diagnosis and patient monitoring. Research has found that cancer and metastases exhibit abnormal expression of numerous non-coding RNA. Some of these RNA facilitate prostate cancer bone metastasis by activating downstream signaling pathways, while others inhibit this process. Elucidating the functional processes of non-coding RNA in prostate cancer bone metastasis will likely lead to innovative treatment strategies for this malignant condition. In this review, the mechanistic role of the various RNA in prostate cancer is examined. Our goal is to provide a new avenue of approach to the diagnosis and treatment of bone metastasis in this cancer.

show abstract

“…Bone metastatic is a malignant tumor in bone due to the easily metastatic characteristic, and its incidence is increasing worldwide [1][2][3]. The cancer cells, such as breast carcinoma and prostatic carcinoma, metastasize easily to bone tissue due to the suitable proliferation conditions of bone tissue for carcinoma cells [4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

GLUT1-mediated magnetic liposomes for targeting bone metastatic breast cancer

2023

European Journal of Gynaecological Oncology

View full text Add to dashboard Cite

Bone metastatic breast cancer is a malignant tumor in bone due to the metastasis of breast cancer, and its incidence is increasing worldwide. Treatment of cancer metastasized to bone is still a challenge because of the anticancer drugs lack target specificity. Finding an effective treatment for bone metastasis remains an urgent issue. In order to enhance the delivery of paclitaxel (PTX) to the bone metastases lesions, a novel glucose derivative was designed and synthesized in this work, which was used as liposome ligand to develop the magnetic liposome G-MLip (Glucose-modified magnetic liposome). The liposome could improve the drug formulations in the bone metastases mediated by glucose transporter 1 (GLUT1) and then target cancer cells. The PTX-loaded magnetic liposome PTX-G-MLip was prepared by the film hydration-ultrasound method. And the characterizations, such as size, zeta potential, encapsulation efficiency, release profile, stability, hemolysis, were well evaluated. What’s more, the enhanced target ability was also investigated in vitro and in mice. The metastatic bone-targeted capacity was confirmed that the PTX concentration from PTX-G-MLip in the bone metastases lesions was markedly increased in the presence of magnetic field (MF) compared with the free PTX and other liposomes. Inspired by the enhanced targeting ability, glucose-modified magnetic liposomes could serve as an effective drug delivery system for targeting and treating bone metastases.

show abstract

microRNA-145-5p inhibits prostate cancer bone metastatic by modulating the epithelial-mesenchymal transition

Cited by 4 publications

References 35 publications

Trillin-Mediated Inhibition of NF-κB/COX-2 Signaling Pathways through Upregulation of miR-145-5p Targeting MAP3K11 in Castration-Resistant Prostate Cancer

Trillin-Mediated Inhibition of NF-κB/COX-2 Signaling Pathways through Upregulation of miR-145-5p Targeting MAP3K11 in Castration-Resistant Prostate Cancer

The regulatory process and practical significance of non-coding RNA in the dissemination of prostate cancer to the skeletal system

GLUT1-mediated magnetic liposomes for targeting bone metastatic breast cancer

Contact Info

Product

Resources

About